SCHEMBL29324694

SCHEMBL29324694

N#Cc1cc(N2CCCCC2)ncn1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
RAB9A P51151 3/20 0.49
NPC1 O15118 2/20 0.49
TSHR P16473 1/20 0.49
RECQL P46063 1/20 0.49
GPR119 Q8TDV5 1/20 0.48
AR P10275 1/20 0.48
CHEK1 O14757 2/20 0.43
P4HTM Q9NXG6 3/20 0.43
RIPK1 Q13546 2/20 0.42
POLB P06746 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
ELOVL1 Q9BW60 2/20 0.40
KDR P35968 2/20 0.40
CHEK2 O96017 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27226303 0.83 KDR (0.53) GPR119CHEK1RIPK1ALDH1A1KDR
SCHEMBL19548104 0.80 SMN1; SMN2 (0.61) SMN1; SMN2RAB9ANPC1TSHRRECQL
SCHEMBL16894243 0.80 P4HTM (0.45) GPR119CHEK1P4HTMRIPK1CHEK2
SCHEMBL27226900 0.78 GPR119 (0.54) SMN1; SMN2NPC1GPR119CHEK1RIPK1
SCHEMBL21783486 0.77 GPR119 (0.53) GPR119ARCHEK1RIPK1KDR
SCHEMBL16635426 0.77 GPR119 (0.53) GPR119ARCHEK1RIPK1KDR
SCHEMBL25260940 0.76 GPR119 (0.58) GPR119CHEK1RIPK1CHEK2
SCHEMBL30339666 0.76 GPR119 (0.58) GPR119CHEK1RIPK1CHEK2
SCHEMBL3617657 0.76 GPR119 (0.58) GPR119ARCHEK1RIPK1ALDH1A1
SCHEMBL3486651 0.75 GPR119 (0.57) GPR119ARCHEK1RIPK1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239797-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 SMN1; SMN2 2237/4885RAB9A 1160/4885NPC1 1743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.